Isto Holdings, the parent company of Isto Technologies, announced it has acquired Arteriocyte Medical Systems Inc. and will integrate the companies under the name Isto Biologics.
According to a press release, Isto Biologics will offer evidence-based solutions to expand its orthopedics, spine and functional-medicine product portfolios. The company will be headquartered in St. Louis, and operations will be maintained in Massachusetts.
“We are grateful for the support of Thompson Street Capital Partners and excited to lead Isto Biologics into the future,” George Dunbar, current chief executive officer (CEO) of Isto Technologies and slated CEO of Isto Biologics, said in the release. “The integration of Isto and Arteriocyte presents an opportunity to leverage our combined expertise to establish a strong position in the ever-changing market and better serve our physician partners, as they work to grow their practice and meet the demands of value-based health care.”